A Phase 2 interventional study of Carbidopa Low-Dose and Placebo in Dysautonomia, Familial and Baroreflex Failure Syndrome, sponsored by NYU Langone Health. Completed at 2 sites in United States. Open to participants aged 10 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypertension by NYU Langone Health — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · NYU Langone Health.
Among the 44 studies in Hypertension by NYU Langone Health, this one is the 37th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2015, is one of 3 in phase 2, and was the 20th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →6 of the 44 studies in Hypertension by NYU Langone Health are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in Kenya
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18–99 · Women only
NYU Langone Health · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 21+
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 10 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 300 across the 39 interventional studies, 114 across the 5 observational. Of the 36 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
2 of the studies in Hypertension by NYU Langone Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06511479NYU Langone HealthJackson Heart Study Women's Hypertension Study | 2027-05-30 |
| NCT05208450NYU Langone HealthActions to Decrease Disparities in Risk and Engage in Shared Support for Blood Pressure Control (ADDRESS-BP) in Blacks | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Hypertension by NYU Langone Health, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated blood pressure variability in patients with familial dysautonomia (FD, also called hereditary sensory and autonomic neuropathy type III or Riley-Day syndrome). Funding Source- FDA OOPD.
The investigators propose to perform a double-blind randomized trial with a cross over design to compare high dose (600 mg/day) and low dose (300 mg per day) carbidopa blockade with placebo. Patients will be randomly assigned to a high-dose/low-dose/placebo sequence, lowdose/placebo/high-dose sequence or placebo/high-dose/low-dose sequence. Participants will remain on each treatment period for 28-days.
Aim 1: To evaluate the safety and tolerability of carbidopa in FD patients with particular emphasis on the orthostatic fall in blood pressure.
Aim 2: As proof of concept, examine the hemodynamic effects of carbidopa and determine its effects on norepinephrine production, BP variability and paroxysmal hypertension.
Aim 3: In a dose finding study, compare the effects of low (300 mg/day) and high (600 mg/day) dose carbidopa blockade vs. placebo on BP variability and paroxysmal hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Unstable blood pressure, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo
Other: Placebo
Drug: Carbidopa Low-Dose
Drug: Carbidopa High-Dose
300 mg/day
Also known as: Lodosyn ®, DL-α-methyl-α-hydrazino-3, 4-dihydroxyphenyl-propionic acid, HMD, MK-486
A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
Also known as: Placebo control pill
600 mg/day
Also known as: Lodosyn ®, DL-α-methyl-α-hydrazino-3, 4-dihydroxyphenyl-propionic acid, HMD, MK-486
Number of Participants Who Reported Adverse Events Related to Study Drug
Adverse events defined as: a change in a patient's baseline condition including intercurrent illnesses irrespective of the relationship to carbidopa treatment. This will be monitored primarily with phone calls at weekly intervals. In addition, patients will be asked about adverse events while at the office. Patients will also fill a daily diary with a specific prompts to note any adverse events.
Time frame: Up to 90 days
Number of Participants With Significant Changes in Body Mass That Resulted in Discontinuation From the Study.
Body mass measured in kg
Time frame: Up to 90 days
Number of Participants With Abnormal Electrocardiographic Interval Patterns
Clinically significant changes in the intervals of characteristic electrocardiographic patterns
Time frame: Up to 90 days
Average Systolic Blood Pressure Variability (Daytime)
Patients with FD undergo ambulatory BP monitoring while keeping a detailed log of their activities (sleep/meal-times/medications/posture/symptoms). Variability in blood pressure overtime will be measured by the standard deviation during awake hours
Time frame: up to Week 14
Highest Systolic Blood Pressure
Maximum blood pressure captured on 24-h ambulatory monitoring
Time frame: Day 1 of treatment period
Systolic Blood Pressure
SBP measured in the seated position
Time frame: up to Week 14
Heart Rate
Heart rate in the seated position
Time frame: up to Week 14
Number of Participants Who Displayed Clinical Significant Laboratory Values on CBC or Metabolic Panel
Clinically significant laboratory values include complete blood count (CMC) and metabolic panel related to treatment with carbidopa
Time frame: Up to 90 days
Number of Participants Who Displayed Clinically Significant Values in Urine Safety Parameters
Clinically significant values on urinalysis, urine safety parameters related to treatment with carbidopa
Time frame: Up to 90 days
Severity of Hypotension During an Active Stand Test
Lowest blood pressure captured during 3 minutes of standing
Time frame: up to Week 14
Number of Participants Who Reported Worsening of OH Symptoms or Dropped Out Because of Worsening OH While on Active Study Drug
Time frame: Up to 90 days
Frequency of Worsening Symptoms Noted in the Patient's Diary
A tailored questionnaire to examine symptoms over the treatment period and the used of as needed medications. Each day will have a designated page. Since nausea/vomiting and hypertension occur together in FD we will use a diary consisting of a simplified version of the Rhodes Index 44 symptoms of nausea/retching, with items addressing vomiting/throwing up omitted, as most participants will have had anti-reflux surgery to prevent vomiting (fundoplication), graded on a 5-point scale (appendix 2). The diary will also include space to write down any adverse events on a daily basis.
Time frame: Up to 90 Days
24-h Urinary Norepinephrine Excretion
Norepinephrine concentration determined from a 24-hour urine sample in a bottle shielded from light containing preservative. Patients will be instructed to refrigerate their sample and bring it on the morning of their visit in a cool bag.
Time frame: up to Week 14
Coefficient of Systolic BP Variability (Daytime)
The measurement of blood pressure variability based on the standard deviation that also takes into account the underlying level of BP.
Time frame: up to Week 14
Morning Surge in Systolic BP on Awakening From Sleep (24-h)
The morning surge will be calculated as the difference between the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep and maximum value detected within 2-h of awakening from sleep
Time frame: up to Week 14
| Milestone | Low-Dose Carbidopa, Then Placebo, Then High-Dose Carbidopa | High-Dose Carbidopa, Then Low-Dose Carbidopa, Then Placebo | Placebo, Then High-Dose Carbidopa, Then Low-Dose Carbidopa |
|---|---|---|---|
| Started | 9 | 7 | 6 |
| Completed | 9 | 7 | 5 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
| Milestone | Low-Dose Carbidopa, Then Placebo, Then High-Dose Carbidopa | High-Dose Carbidopa, Then Low-Dose Carbidopa, Then Placebo | Placebo, Then High-Dose Carbidopa, Then Low-Dose Carbidopa |
|---|---|---|---|
| Started | 9 | 7 | 5 |
| Completed | 8 | 7 | 4 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Milestone | Low-Dose Carbidopa, Then Placebo, Then High-Dose Carbidopa | High-Dose Carbidopa, Then Low-Dose Carbidopa, Then Placebo | Placebo, Then High-Dose Carbidopa, Then Low-Dose Carbidopa |
|---|---|---|---|
| Started | 8 | 7 | 4 |
| Completed | 7 | 7 | 4 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Milestone | Low-Dose Carbidopa, Then Placebo, Then High-Dose Carbidopa | High-Dose Carbidopa, Then Low-Dose Carbidopa, Then Placebo | Placebo, Then High-Dose Carbidopa, Then Low-Dose Carbidopa |
|---|---|---|---|
| Started | 7 | 7 | 4 |
| Completed | 6 | 7 | 3 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
Adverse events defined as: a change in a patient's baseline condition including intercurrent illnesses irrespective of the relationship to carbidopa treatment. This will be monitored primarily with phone calls at weekly intervals. In addition, patients will be asked about adverse events while at the office. Patients will also fill a daily diary with a specific prompts to note any adverse events.
| Participants | Placebo | Low-Dose Carbidopa | High-Dose Carbidopa |
|---|---|---|---|
| Number of Participants Who Reported Adverse Events Related to Study Drug | 0 | 0 | 0 |
Body mass measured in kg
| Participants | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Number of Participants With Significant Changes in Body Mass That Resulted in Discontinuation From the Study. | 0 | 0 | 0 |
Clinically significant changes in the intervals of characteristic electrocardiographic patterns
| Participants | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Number of Participants With Abnormal Electrocardiographic Interval Patterns | 0 | 0 | 0 |
Patients with FD undergo ambulatory BP monitoring while keeping a detailed log of their activities (sleep/meal-times/medications/posture/symptoms). Variability in blood pressure overtime will be measured by the standard deviation during awake hours
| mmHg | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Average Systolic Blood Pressure Variability (Daytime) | 22.92 ± 6.13 | 18.71 ± 4.83 | 16.92 ± 4.14 |
Maximum blood pressure captured on 24-h ambulatory monitoring
| mmHg | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Highest Systolic Blood Pressure | 175 ± 27 | 157 ± 20 | 150 ± 17 |
SBP measured in the seated position
| mmHg | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Systolic Blood Pressure | 126 ± 27 | 126 ± 18 | 126 ± 21 |
Heart rate in the seated position
| beats per minute (BPM) | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Heart Rate | 76 ± 11 | 72 ± 13 | 78 ± 13 |
Clinically significant laboratory values include complete blood count (CMC) and metabolic panel related to treatment with carbidopa
| Participants | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Number of Participants Who Displayed Clinical Significant Laboratory Values on CBC or Metabolic Panel | 0 | 0 | 0 |
Clinically significant values on urinalysis, urine safety parameters related to treatment with carbidopa
| Participants | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Number of Participants Who Displayed Clinically Significant Values in Urine Safety Parameters | 0 | 0 | 0 |
Lowest blood pressure captured during 3 minutes of standing
| mmHg | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Severity of Hypotension During an Active Stand Test | 96 ± 27 | 91 ± 28 | 96 ± 24 |
| Participants | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Number of Participants Who Reported Worsening of OH Symptoms or Dropped Out Because of Worsening OH While on Active Study Drug | 0 | 0 | 0 |
A tailored questionnaire to examine symptoms over the treatment period and the used of as needed medications. Each day will have a designated page. Since nausea/vomiting and hypertension occur together in FD we will use a diary consisting of a simplified version of the Rhodes Index 44 symptoms of nausea/retching, with items addressing vomiting/throwing up omitted, as most participants will have had anti-reflux surgery to prevent vomiting (fundoplication), graded on a 5-point scale (appendix 2). The diary will also include space to write down any adverse events on a daily basis.
| symptoms | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Frequency of Worsening Symptoms Noted in the Patient's Diary | 0 | 0 | 0 |
Norepinephrine concentration determined from a 24-hour urine sample in a bottle shielded from light containing preservative. Patients will be instructed to refrigerate their sample and bring it on the morning of their visit in a cool bag.
| pg/mL | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| 24-h Urinary Norepinephrine Excretion | 16 ± 11 | 6 ± 3 | 8 ± 6 |
The measurement of blood pressure variability based on the standard deviation that also takes into account the underlying level of BP.
| mmHg | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Coefficient of Systolic BP Variability (Daytime) | 19 ± 4 | 16 ± 4 | 15 ± 3 |
The morning surge will be calculated as the difference between the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep and maximum value detected within 2-h of awakening from sleep
| mmHg | Placebo | High-Dose Carbidopa | Low-Dose Carbidopa |
|---|---|---|---|
| Morning Surge in Systolic BP on Awakening From Sleep (24-h) | 44 ± 24 | 19 ± 11 | 20 ± 9 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low-Dose Carbidopa | 1/16 (6.3%) | 1/16 (6.3%) | 4/16 (25%) |
| High-Dose Carbidopa | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Placebo | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Event | Low-Dose Carbidopa | High-Dose Carbidopa | Placebo |
|---|---|---|---|
| HospitaliztionGeneral disorders | 1/16 | 0/16 | 0/16 |
| Event | Low-Dose Carbidopa | High-Dose Carbidopa | Placebo |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 4/16 | 0/16 | 0/16 |
| SyncopeVascular disorders | 0/16 | 3/16 | 0/16 |
| Age, Continuous(years) | Low Dose Carbidopa, High Dose Carbidopa, Placebo |
|---|---|
| Mean | 28 (13 to 58) |
| Sex: Female, Male(Participants) | Low Dose Carbidopa, High Dose Carbidopa, Placebo |
|---|---|
| Female | 14 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Low Dose Carbidopa, High Dose Carbidopa, Placebo |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Low Dose Carbidopa, High Dose Carbidopa, Placebo |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 22 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Low Dose Carbidopa, High Dose Carbidopa, Placebo |
|---|---|
| United States | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Sep 2015, a primary completion of May 2019 and a completion of May 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2022, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.